Research and Markets: Recent Report 'Chugai Pharma Partnering Guide 2008' Provides...

Research and Markets: Recent Report 'Chugai Pharma Partnering Guide 2008' Provides A Firm Basis for Initial Due Diligence into Chugai as A Prospective Partner Company

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/5e7d90/chugai_pharma_part)
has announced the addition of the "Chugai Pharma Partnering Guide
2008" company profile to their offering.

This report provides an in-depth insight into the partnering
interests and activites of one of the worlds leading biopharma
companies. The report provides all the information you require to
better understand Chugai and its partnering interests and activities
over the past five years. One of the key aspects of partnering is
finding those companies that are potential partners for the
development and commercialization of the next generation of therapies
as developed by innovative biopharma R&D companies. A lot of resources
are spent on finding partners, identifying their interests and making
contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently
determine the suitablility of Chugai as a prospective partner, their
business development objectives, interests and recent partnering
activity, key partnering contacts, and partnering contract documents
signed with their recent partners.

The report provides a firm basis for initial due diligence into
Chugai as a prospective partner company.

-0-
*T
Key benefits:

Chugai Partnering Guide 2008 report provides the user with the
following key benefits:

- Detailed company profile of the company
- In-depth marketed and pipeline product activity for the company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 - number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to actual contracts entered into by the company
and its partners(a)
- Insight into the terms included in a partnering agreement
- Understand the key deal terms the company has agreed in previous
deals
- Undertake due diligence to assess suitability of your proposed deal
terms for partner companies

(a) Subject to being published via regulatory requirements of the
Securities Exchange Commission.
*T

Report scope:

Chugai Partnering Guide 2008 is intended to provide the reader
with an in-depth understanding of the partnering activities and
interests of the company, enabling the effective assessment and
selection of partners of choice, based on the latest knowledge of a
company's approach to partnering.

-0-
*T
Chugai Partnering Guide 2008 includes:

Detailed company profile including:
- Full contact details
- Business developer contact details including name, title, email and
telephone (where available)
- Marketed indications
- Pipeline indications
- Partnering interests and indications
- Partnering activity since 2000
- Current partner companies since 2005

Partnering activity since 2005 by:
- Deal type
- Stage of development
- Therapy area
- Numerous charts showing the dealmaking activity of the company since
2005
- The tools to enable effective and efficient preparation for
partnering negotiation with the company
- Listing of contract documents between the company and its partners
- The leading M&A and partnering deals by value 2005-8
- Most active M&A and partnering dealmakers 2005-8

The Chugai Partnering Guide 2008 report also provides comprehensive
access to available contract documents for the company. Analyzing
actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subscontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
*T

Executive Summary:

The initial chapters of this report provide an orientation of
bigpharma's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2
lists the top 50 leading biopharma companies based on 2007
pharmaceutical revenues. Chapter 3 analyses the most active dealmakers
between 2005 and 2007 in M&A and partnering deals announced, whilst
chapter 4 identifies the top deals of 2005-7 according to reported
deal size.

Chapter 5 provides details on how to approach bigpharma companies
with partnering opportunities whilst chapter 6 lists forthcoming
partnering events and conferences where bigpharma companies will be
present to discuss opportunities face to face.

Chapter 7 provides a series of matrices that summarize the
company's activity in terms of marketed and pipeline products,
partnering interests and partnering activity by therapeutic area. The
main body of the report is provided in chapter 8. An in-depth profile
of the company provides everything required to assess the suitability
of a company as a prospective partner. This includes a company
overview, detailed analysis of the company's marketed and pipeline
disease targets, partnering interests, partnering activity according
to deal type, phase of development, therapy area. The profile also
includes in-depth contact information for individuals within the
business development function.

The company profile is also provided with a comprehensive listing
of contract documents available in the public domain. The listing is
sorted by deal type - therefore co-promotion deals are listed
separately to licensing, M&A and supply deals, and so on. Each deal
title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
In summary, the report provides the user with the tools to make
successful contact with the right bigpharma partners effectively and
efficiently.

-0-
*T
Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Bigpharma - The Top 50

Chapter 3 - Most active bigpharma dealmakers
3.1 Bigpharma M&A activity
3.2 Bigpharma partnering

Chapter 4 - Top bigpharma deals - 2000-7
4.1 Bigpharma M&A
4.2 Bigpharma partnering

Chapter 5 - Submitting Opportunities to Bigpharma such as Chugai
5.1 How to submit an opportunity
5.2 Opportunity submission template
5.3 Sending emails
5.4 Face to face at partnering events
5.5 Online submission forms

Chapter 6 - Forthcoming bigpharma partnering events
6.1 Forthcoming events

Chapter 7 - Chugai Pharmaceuticals - therapy locator
7.1 How to use the therapy matrix tables
7.2 Therapeutic area definitions
7.3 Bigpharma - Therapeutic target matrix - marketed and pipeline
compounds
7.5 Bigpharma - Therapeutic target matrix - expressed partnering
interests
7.6 Bigpharma - Therapeutic target matrix - recent deals - 2005-2007

Chapter 8 - Bigpharma Company Profiles
8.1 How to use company profiles
8.2 Field definitions
8.3 Chugai company profile
Company contact details
Subsidiary companies
Primary therapy areas
Business development contacts
Company description
Marketed therapeutic indications
Pipeline (phase I-III) therapeutic indications
Partnering interests
Partnering interests - therapeutic indications
Partnering frequency per annum - 2000-2008
Current partner companies (2005-8)
Recent deals 2005-2008
By deal type
By stage of development
By therapy area
Contract documents available online - link direct to each document

Figures in report:

Figure 1: Bigpharma - top 50 by pharma revenues 2007
Figure 2: Leading Bigpharma M&A companies, 2005-7
Figure 3: Leading Bigpharma partnering companies, 2005-7
Figure 4: Leading M&A deals involving bigpharma by value, 2005-7
Figure 5: Leading partnering deals by value, 2005-7
Figure 6: Typical partnering opportunity submission template
Figure 7: Partnering events 2008-9
Figure 8: Therapeutic area definitions
Figure 9: Therapeutic target matrix - marketed and pipeline compounds
Figure 10: Therapeutic target matrix - expressed partnering interests
Figure 11: Therapeutic target matrix - recent deals 2005-7
Figure 12: Company profile template and definitions used in report
Figure 13: Chugai - Dealmaking frequency 2000-2007
Figure 14: Chugai - recent deals (2005-2008) by deal type
Figure 15: Chugai - recent deals (2005 - 2008) by stage of development
Figure 16: Chugai - recent deals (2005 - 2008) by therapy area
Figure 17: Recent Chugai partnering deals (2003-2008) where contract
document available
Figure 18: Online partnering resources
*T

For more information visit
http://www.researchandmarkets.com/research/5e7d90/chugai_pharma_part

Research and Markets
Laura Wood, Senior Manager, press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2008